ASCO22 Metastatic Breast Cancer Updates | Sramila Aithal, MD | US Oncology

Antibody Drug Conjugates in Metastatic Breast Cancer | Dr.Sramila Aithal, MD US OncologyПодробнее

ASCO22 Metastatic Breast Cancer Updates | Lee Schwartzberg, MD | Renown Institute for CancerПодробнее

Antibody Drug Conjugates in Metastatic Breast Cancer | Sramila Aithal, MD | ESMO22 PennsylvaniaПодробнее

Metastatic Breast Cancer Updates I Dr.Sramila Aithal, MD US OncologyПодробнее

ASCO22 Early Stage Breast Cancer Updates | Aixa Soyano, MD| Moffitt Cancer CenterПодробнее

Radiation Therapy Based on LUMINA Trial | Cynthia Ma, MD, PhD | ASCO22 Breast Cancer UpdatesПодробнее

Dr. Sramila Aithal on the EMILIA Trial Studying T-DM1 in Metastatic Breast CancerПодробнее

Effectiveness of TDXD vs. Sacituzumab for ER+ Breast Cancer | Jane Meisel, MD | ASCO22 UpdatesПодробнее

ASCO22 Metastatic Breast Cancer Updates | Anthony Elias, MD | University of ColoradoПодробнее

Dr. Aithal on Breast Cancer SubtypesПодробнее

ASCO 2022: Metastatic Breast Cancer Drug Therapy RecapПодробнее

Dr. Sramila Aithal MD; Director Breast Cancer of Advanced Oncology; Shares Life's Journey & DevotionПодробнее

Dr. Sramila Aithal on the AE37 Peptide Vaccine in Breast CancerПодробнее

Sramila Aithal, MD | Neratinib and Dose Escalation | Optimizing Therapy for HER2+ DiseaseПодробнее

ASCO22: Breast cancer research by Sara Tolaney, MD | Dana-Farber Cancer InstituteПодробнее

ASCO22 Early-Stage Breast Cancer Updates | Rebecca Shatsky, MD | University of California San DiegoПодробнее

ASCO22 Metastatic Lung Cancer Updates | Erminia Massarelli, MD, PhD | City of HopeПодробнее

Breast cancer highlights from the 2022 ASCO Annual Meeting | Harold BursteinПодробнее

Dr. Sramila Aithal Describes the HERceptin Adjuvant (HERA) Trial for HER2-Positive Breast CancerПодробнее